Tilray Brands (NASDAQ:TLRY) Announces Quarterly Earnings Results

Tilray Brands (NASDAQ:TLRY) released its quarterly earnings data on Tuesday. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.42), Zacks reports. The company had revenue of $281.71 million for the quarter, compared to the consensus estimate of $246.30 million. Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%.

Here are the key takeaways from Tilray Brands’ conference call:

• Record fiscal-year performance: Revenue rose 11% to $915.5 million, adjusted EBITDA increased 11% to $61.1 million, and fourth-quarter adjusted EBITDA reached a record $31.9 million. Management guided to fiscal 2027 adjusted EBITDA of $68 million to $75 million.
• International cannabis remained a major growth engine: Medical cannabis revenue grew 34% to $84.9 million, with notable growth in Germany, the U.K., Poland, and Italy. Portugal utilization reached approximately 80%, while the company said expanded supply and faster permitting could support further growth.
• BrewDog expanded Tilray’s beverage platform: The acquisition contributed $51.1 million of fourth-quarter revenue and adds more than $200 million in annualized revenue, pubs, and international distribution. Tilray also expects to begin brewing and distributing Carlsberg brands in the U.S. on January 1, 2027.
• Profitability remains under pressure in parts of the portfolio: International cannabis faced approximately $21.1 million of price compression, beverage gross margin declined to 36% from 39%, and the legacy U.S. beer business experienced industry headwinds and a 17% organic fourth-quarter revenue decline excluding BrewDog. Management is targeting cost reductions and margin expansion to address these issues.
• Balance-sheet flexibility improved, but cash generation is not yet positive after investments: Tilray ended the year with $234.6 million in cash, marketable securities, and restricted cash, while net debt fell to less than $1 million. However, adjusted free cash flow remained negative at $86 million for the year, primarily due to BrewDog working-capital needs and strategic capital investments.

Tilray Brands Stock Down 4.1%

TLRY stock traded down $0.17 on Wednesday, hitting $3.87. 3,978,702 shares of the company’s stock were exchanged, compared to its average volume of 4,215,167. The firm has a 50 day moving average price of $4.74 and a two-hundred day moving average price of $6.34. Tilray Brands has a 12-month low of $3.67 and a 12-month high of $23.20. The stock has a market cap of $450.47 million, a P/E ratio of -0.28 and a beta of 1.89. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.66 and a current ratio of 2.79.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tidal Investments LLC raised its stake in Tilray Brands by 15.0% in the 2nd quarter. Tidal Investments LLC now owns 28,971,835 shares of the company’s stock worth $12,006,000 after acquiring an additional 3,776,410 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Tilray Brands by 281.0% in the third quarter. Millennium Management LLC now owns 4,942,319 shares of the company’s stock valued at $8,550,000 after purchasing an additional 3,645,060 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Tilray Brands in the third quarter worth about $5,813,000. Ausdal Financial Partners Inc. acquired a new stake in shares of Tilray Brands during the second quarter worth about $939,000. Finally, Scientech Research LLC acquired a new position in Tilray Brands in the 3rd quarter worth approximately $1,748,000. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Trending Headlines about Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray reported record fiscal 2026 revenue of approximately $915 million and record adjusted EBITDA, highlighting growth across cannabis, beverages, hospitality and wellness. International medical cannabis revenue increased 34% for the year. Tilray fiscal 2026 results
• Positive Sentiment: Management projected fiscal 2027 adjusted EBITDA of $68 million to $75 million, representing anticipated double-digit growth and signaling a focus on margin expansion. Tilray fiscal 2027 EBITDA guidance
• Positive Sentiment: The BrewDog acquisition is expected to expand Tilray’s global beverage platform and provide additional opportunities through brands, hospitality and consumer experiences. The company also reported approximately $235 million in cash, restricted cash and marketable securities, with net debt reduced to about $0.7 million. Tilray diversified platform update
• Neutral Sentiment: Fourth-quarter revenue rose 25.5% year over year to $281.7 million, exceeding estimates near $246 million, while gross profit increased 33.8% to $90.5 million. However, the stronger sales did not translate into bottom-line profitability.
• Negative Sentiment: Tilray posted a fourth-quarter loss of $0.43 per share, substantially worse than the approximately $0.01–$0.02 loss analysts expected and below the prior-year profit. Net loss attributable to common shareholders was $49.6 million, while operating loss widened to $16.5 million. Tilray fourth-quarter earnings report
• Negative Sentiment: Operating cash flow was negative $37.3 million during the quarter, raising concerns about the company’s ability to convert revenue growth into sustainable cash generation. The large EPS miss appears to be the primary reason the stock is under pressure despite the record sales and forward EBITDA outlook. Tilray earnings surprise analysis

Wall Street Analysts Forecast Growth

TLRY has been the subject of a number of recent research reports. ATB Cormark Capital Markets dropped their price objective on shares of Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating for the company in a research note on Thursday, April 2nd. Weiss Ratings lowered Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Roth Capital upgraded Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Thursday, April 2nd. Finally, TD Cowen reduced their target price on Tilray Brands from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $11.00.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.